Biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation
Grey Wolf Therapeutics has raised €87M across 2 funding rounds from 7 investors, most recently a Series B round in May 2024. Based in Oxford, UK; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
